Eurofins Scientific


Core business accelerates, while COVID-19 revenue subsides but remains robust

28/04/21 -"Eurofins continued its strong showing with 44.3% organic top-line growth in Q1, building on its robust performance in the second half of last year. The share price came under pressure on the back of ..."

Pages
46
Language
English
Published on
28/04/21
You may also be interested by these reports :
10/06/21
Following the group’s trading update at its recent CMD, our previous forecasts appear to be too conservative, so, we have upgraded our forecasts to ...

04/06/21
April was another impressive month for Eurofins with sustained COVID-19-related revenue and accelerated organic growth momentum in the core business, ...

19/05/21
Experian’s FY20/21 results were ahead of headline figures. Revenue grew c.4% (in organic terms), led by the robust mortgage refinancing activity in ...

05/05/21
Securitas had a mitigated Q1 21 with flat organic sales due to weaknesses in the Security Services Europe and Ibero-America and a strong increase in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO